Neuromuscular Disorders

Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trial

Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities

By

All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

Glatiramer Acetate Associated With Long-Term Disability Improvements in MS

By

Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study

By

Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis

By

Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.

High-Dose Biotin May Be an Effective Treatment for Progressive MS

High-Dose Biotin May Be an Effective Treatment for Progressive MS

By

Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.

MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

MS Relapse Rates After DMT Initiation Similar Between Pediatric-, Adult-Onset MS

By

Disability progression is slower among patients with pediatric-onset multiple sclerosis.

Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS

By

In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.

Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

Disease Modifying Therapy Associated With Persistent Brain Atrophy Slowing in MS

By

Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.

Patients With Multiple Sclerosis Face Greater Infection Risk

Patients With Multiple Sclerosis Face Greater Infection Risk

By

Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.

Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

Alemtuzumab Improves Disability, Prognosis in Treatment-Refractory MS

By

Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.

Fingolimod Significantly Improves Quality of Life in Pediatric MS

Fingolimod Significantly Improves Quality of Life in Pediatric MS

By

The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.

Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes

Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes

By

Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.

Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

By

Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).

Copaxone 3 Times Weekly Safe, Effective for Ambulatory Patients With Relapsing MS

Copaxone 3 Times Weekly Safe, Effective for Ambulatory Patients With Relapsing MS

By

Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.

Serious Adverse Events Profile for Cladribine Confirmed With Extended Data

Serious Adverse Events Profile for Cladribine Confirmed With Extended Data

By

Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.

Multiple Sclerosis Comorbidities Affect Work Participation, Daily Function

Multiple Sclerosis Comorbidities Affect Work Participation, Daily Function

By

Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.

Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis

Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis

By

Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.

Risk for Acute Myocardial Infarction Increased in Multiple Sclerosis

Risk for Acute Myocardial Infarction Increased in Multiple Sclerosis

By

Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.

Cladribine Tablets Reduce Relapses in Relapsing-Remitting Multiple Sclerosis

Cladribine Tablets Reduce Relapses in Relapsing-Remitting Multiple Sclerosis

By

Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.

Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

By

Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.

Dimethyl Fumarate Therapy Reduces Relapse Rates in Early Multiple Sclerosis

Dimethyl Fumarate Therapy Reduces Relapse Rates in Early Multiple Sclerosis

By

The ESTEEM study included 3075 patients who were newly prescribed dimethyl fumarate to manage relapsing-remitting multiple sclerosis.

Early Disease Modifying Therapy Initiation Associated With Improved MS Relapse Control

Early Disease Modifying Therapy Initiation Associated With Improved MS Relapse Control

By

Early initiation of dimethyl fumarate and fingolimod may be associated with improved relapse control in multiple sclerosis relative to late therapy initiation.

Extended Interval Dosing of Natalizumab Does Not Reduce Efficacy in MS

Extended Interval Dosing of Natalizumab Does Not Reduce Efficacy in MS

By

Extended interval dosing of natalizumab may also be associated with reduced risk for progressive multifocal leukoencephalopathy.

Patients With MS Who Use Tobacco at Greater Risk for Disease Activity

Patients With MS Who Use Tobacco at Greater Risk for Disease Activity

By

Multiple sclerosis disease activity was less likely to decrease among tobacco users.

Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis

Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis

By

Previous studies have shown that excess adiposity is a strong risk factor for metabolic comorbidities and has been linked to poorer outcomes in people with neurologic diseases.

Exploring the Benefits of Virtual Reality Rehabilitation in Multiple Sclerosis

Exploring the Benefits of Virtual Reality Rehabilitation in Multiple Sclerosis

By

Future studies on VR training for MS should include large randomized controlled trials using clear protocols and comparable between-group tasks.

Lower Levels of Depression, Higher QOL for Older MS Patients

Lower Levels of Depression, Higher QOL for Older MS Patients

Older individuals with multiple sclerosis report less severe depressive symptoms and better physical quality of life, compared to younger patients.

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in Multiple Sclerosis

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in Multiple Sclerosis

By

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.

AANEM 2018: Key Programming on Neuromuscular and Electrodiagnostic Medicine

AANEM 2018: Key Programming on Neuromuscular and Electrodiagnostic Medicine

By

The 2018 AANEM Annual Meeting is taking place at the Gaylord National Resort & Convention Center in Washington, DC.

Sign Up for Free e-newsletters



CME Focus